1,723.00
+16.5(+0.97%)
Currency In JPY
Address
8-2, Kyutaromachi 1-chome
Osaka, 541-8564
Japan
Phone
81 6 6263 5670
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
3853
First IPO Date
January 04, 2001
| Name | Title | Pay | Year Born |
| Mr. Gyo Sagara | Chief Executive Officer & Chairman of the Board | 142M | 1958 |
| Hiromu Habashita Ph.D. | Corporate Officer & Deputy Executive Director, Discovery & Research | 0 | N/A |
| Shinji Takai M.D., Ph.D. | Corporate Officer & Head of Medical Affairs | 0 | N/A |
| Mr. Toichi Takino Ph.D. | President, Chief Operating Officer & Representative Director | 0 | 1968 |
| Takehiro Yamada | Corporate Officer & Head of Risk and Compliance Management Department | 0 | N/A |
| Akira Takada | Corporate Executive Officer &Exe. Dir. of CMC & Production | 0 | N/A |
| Mr. Masaki Ito | Corporation Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., and Corp. Tax | 0 | N/A |
| Masayuki Tanigawa | Corporate Officer & Head of Business Strategy Headquarters | 0 | N/A |
| Satoshi Takahagi | Senior Director of EHS Promotion & Corporate Executive Officer | 0 | N/A |
| Mr. Tatsuya Okamoto | Head of Development Div., Oncology Clinical Development Div. & Global Development Management Unit | 0 | N/A |
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.